The CEO of Swiss not-for-profit foundation EspeRare tells Scrip how she will use funds generated from a co-development pact with Dermelix Biotherapeutics to create novel in utero treatments for rare genetic diseases.

Derived from Strategic Transactions, a premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced November through December 2014.

Recent executive-level hires and director appointments at venture capital firms and biopharma and medtech start-ups.

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Recent Financings Of Private Companies column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors.